

A leading developer of next generation synthetic binders delivering innovation to the life science industry



Who we are

Using multiple affinity binder discovery platforms, we are empowering scientists to unlock new drug targets and advance superior diagnostics and medicines.

Through innovation, a strong intellectual property portfolio, and global partnerships, we drive scientific breakthroughs that improve healthcare outcomes.

Our vision

Better drugs and diagnostics delivered via innovative technology, strategic partnerships, and a commitment to delivering lasting value for patients, partners, and shareholders.

Recognised as a key global player in aptamer development¹

2 proprietary discovery platforms for custom binders

10 developed Optimer[®] assets

28 partners across the globe in FY 2024

75+ years of collective experience

100% of top ten pharma companies we have served

2021 listed on AIM

2008 incorporated

optimer[®]


Automated, high-throughput discovery and development platforms for optimized DNA and RNA aptamers.

Established binder modality from research to approved therapies.

Technical advantages

- Broader target applicability
- Tuneable selectivity and tailored to end application
- Up to 75% faster development
- Scalable, cost-effective production
- Synthetic manufacture allows better quality control
- Animal-free development and downstream manufacture

Business model



Compatible with multiple segments of the life science market and beyond

Working in the \$210bn affinity ligand market, our technology is being applied across various sectors for diverse applications.

Research


Diagnostics

Cosmetics

Bioprocessing

Therapeutics

Asset portfolio



¹ Meditech Insights, Aptamer Market Size & Forecast, 2024; Research & Markets, ID: 5782939, 2024

Diverse and partnered asset portfolio developed through fee-for-service contracts

Each asset programme is partnered with global leaders supporting:

- expert insight in specific fields
- market penetrance of final product
- potential high-value licensing and royalty revenue



Group retains ownership of IP in relation to binders



150%
Increase in licensable assets over last year



Partnered assets provide expert insight in specific segments

60-70%
Success rate on binder development



Fee-for-service development acts as a horizon scanning platform

Tools

Enzyme modulating Optimers

\$9.2bn

Addressable market value

2

External labs have demonstrated performance

2025

First licensing agreement expected

3 global life science suppliers

Critical reagent for drug development



Generated to support active drug development



Under evaluation with top pharma partner

Top 3 pharma company

Diagnostics

Alzheimer's disease diagnostic

\$8.3bn

Alzheimer's disease diagnostic market value



Proven to identify Alzheimer's disease



High single digit royalties proposed



Fetal diagnostics

\$6.4bn

Addressable market value



Enables safer fetal tests

2

Partners evaluating for diagnostic development

Global clinical diagnostic company

Optimizer active ingredients in deodorants

\$26.96bn

Deodorant market value

#1

Partnered with leader in deodorant market



Skin testing initiated in Dec 2024



Unilever

Cosmetics

Fibrotic liver delivery vehicle

\$14.7bn

Global market for liver fibrosis



Proven functionality for gene therapies



Entering preclinical phase in 2025

AstraZeneca

Therapeutics

Genetic medicine delivery vehicle

\$9.3bn

Global market for gene therapy



Proven success in customers labs

Genetic medicine company

siRNA delivery vehicle

\$9.3bn

Global market for gene therapy

RNAi company

Financial Highlights

133%
revenue increase

£3.4m
advanced stage sales pipeline

£3.0m
cost base

Nil
debt

c.£5m
Market capitalisation

Revenue by geographical market

USA



69%

Europe & UK



19%

ROW



12%